메뉴 건너뛰기




Volumn 18, Issue , 2014, Pages 9-17

Treatment of HCV infection with the novel NS3/4A protease inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

ABT 450; ASUNAPREVIR; BOCEPREVIR; DELDEPREVIR; FALDAPREVIR; GRAZOPREVIR; MERICITABINE; MK 5172; NARLAPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR; VEDROPREVIR; DACLATASVIR; DANOPREVIR; DASABUVIR; DELEOBUVIR; LEDIPASVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMBITASVIR; PLACEBO; SOFOSBUVIR; SOVAPREVIR; TEGOBUVIR; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; NS4B PROTEIN, FLAVIVIRUS; VIRUS PROTEIN;

EID: 84907302681     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.07.016     Document Type: Review
Times cited : (26)

References (52)
  • 1
    • 78751621217 scopus 로고    scopus 로고
    • Evolving epidemiology of hepatitis C virus
    • D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 2011 107 115
    • (2011) Clin Microbiol Infect , vol.17 , pp. 107-115
    • Lavanchy, D.1
  • 2
    • 23944506014 scopus 로고    scopus 로고
    • Global epidemiology of hepatitis C virus infection
    • DOI 10.1016/S1473-3099(05)70216-4, PII S1473309905702164
    • C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 2005 558 567 (Pubitemid 41196755)
    • (2005) Lancet Infectious Diseases , vol.5 , Issue.9 , pp. 558-567
    • Shepard, C.W.1    Finelli, L.2    Alter, M.J.3
  • 3
    • 33646250428 scopus 로고    scopus 로고
    • The natural history of hepatitis C virus (HCV) infection
    • S.L. Chen, and T.R. Morgan The natural history of hepatitis C virus (HCV) infection Int J Med Sci 3 2006 47 52
    • (2006) Int J Med Sci , vol.3 , pp. 47-52
    • Chen, S.L.1    Morgan, T.R.2
  • 4
    • 77953607625 scopus 로고    scopus 로고
    • Pegylated-interferon plus ribavirin therapy in the treatment of CHC: Individualization of treatment duration according to on-treatment virologic response
    • S. Zeuzem, and F. Poordad Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response Curr Med Res Opin 26 2010 1733 1743
    • (2010) Curr Med Res Opin , vol.26 , pp. 1733-1743
    • Zeuzem, S.1    Poordad, F.2
  • 5
    • 84898990930 scopus 로고    scopus 로고
    • New hepatitis C therapies: The toolbox, strategies, and challenges
    • J. Pawlotsky New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146 2014 1176 1192
    • (2014) Gastroenterology , vol.146 , pp. 1176-1192
    • Pawlotsky, J.1
  • 6
    • 84901586232 scopus 로고    scopus 로고
    • Hepatitis C treatment: An incipient therapeutic revolution
    • 10.1016/j.molmed.2014.02. 002
    • A.S. deLemos, and R.T. Chung Hepatitis C treatment: an incipient therapeutic revolution Trends Mol Med 2014 10.1016/j.molmed.2014.02. 002
    • (2014) Trends Mol Med
    • Delemos, A.S.1    Chung, R.T.2
  • 8
    • 84872044131 scopus 로고    scopus 로고
    • New therapeutic strategies in HCV: Second-generation protease inhibitors
    • V.C. Clark, J.A. Peter, and D.R. Nelson New therapeutic strategies in HCV: second-generation protease inhibitors Liver Int 33 Suppl. 1 2013 80 84
    • (2013) Liver Int , vol.33 , Issue.SUPPL. 1 , pp. 80-84
    • Clark, V.C.1    Peter, J.A.2    Nelson, D.R.3
  • 14
    • 84882908504 scopus 로고    scopus 로고
    • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
    • C. Hézode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, V. Canva, V. de Ledinghen, T. Poynard, D. Samuel, and M. Bourlière et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
    • (2013) J Hepatol , vol.59 , pp. 434-441
    • Hézode, C.1    Fontaine, H.2    Dorival, C.3    Larrey, D.4    Zoulim, F.5    Canva, V.6    De Ledinghen, V.7    Poynard, T.8    Samuel, D.9    Bourlière, M.10
  • 16
    • 84879795434 scopus 로고    scopus 로고
    • Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial
    • M. Sulkowski, S. Pol, J. Mallolas, H. Fainboim, C. Cooper, J. Slim, A. Rivero, C. Mak, S. Thompson, and A.Y.M. Howe et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial Lancet Infect Dis 13 2013 597 605
    • (2013) Lancet Infect Dis , vol.13 , pp. 597-605
    • Sulkowski, M.1    Pol, S.2    Mallolas, J.3    Fainboim, H.4    Cooper, C.5    Slim, J.6    Rivero, A.7    Mak, C.8    Thompson, S.9    Howe, A.Y.M.10
  • 17
    • 84891825080 scopus 로고    scopus 로고
    • Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection
    • D.E. Karageorgopoulos, O. El-Sherif, S. Bhagani, and S.H. Khoo Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection Curr Opin Infect Dis 27 2014 36 45
    • (2014) Curr Opin Infect Dis , vol.27 , pp. 36-45
    • Karageorgopoulos, D.E.1    El-Sherif, O.2    Bhagani, S.3    Khoo, S.H.4
  • 19
    • 84879693219 scopus 로고    scopus 로고
    • Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
    • Y. Suzuki, K. Ikeda, F. Suzuki, J. Toyota, Y. Karino, K. Chayama, Y. Kawakami, H. Ishikawa, H. Watanabe, and W. Hu et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J Hepatol 58 2013 655 662
    • (2013) J Hepatol , vol.58 , pp. 655-662
    • Suzuki, Y.1    Ikeda, K.2    Suzuki, F.3    Toyota, J.4    Karino, Y.5    Chayama, K.6    Kawakami, Y.7    Ishikawa, H.8    Watanabe, H.9    Hu, W.10
  • 21
    • 84885308430 scopus 로고    scopus 로고
    • Drug-drug interactions during antiviral therapy for chronic hepatitis C
    • J. Kiser, J. Burton, and G. Everson Drug-drug interactions during antiviral therapy for chronic hepatitis C Nat Rev Gastroenterol Hepatol 10 2013 596 606
    • (2013) Nat Rev Gastroenterol Hepatol , vol.10 , pp. 596-606
    • Kiser, J.1    Burton, J.2    Everson, G.3
  • 23
    • 84879189258 scopus 로고    scopus 로고
    • A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment
    • E. Lawitz, M. Rodriguez-Torres, A. Stoehr, E.J. Gane, L. Serfaty, S. Bhanja, R.J. Barnard, D. An, J. Gress, and P. Hwang et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment J Hepatol 59 2013 11 17
    • (2013) J Hepatol , vol.59 , pp. 11-17
    • Lawitz, E.1    Rodriguez-Torres, M.2    Stoehr, A.3    Gane, E.J.4    Serfaty, L.5    Bhanja, S.6    Barnard, R.J.7    An, D.8    Gress, J.9    Hwang, P.10
  • 24
    • 84903126518 scopus 로고    scopus 로고
    • Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis
    • M. Rodriguez-Torres, A. Stoehr, E.J. Gane, L. Serfaty, E. Lawitz, A. Zhou, M. Bourque, S. Bhanja, J. Strizki, and R.J.O. Barnard et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis Clin Gastroenterol Hepatol 3565 2013
    • (2013) Clin Gastroenterol Hepatol , vol.3565
    • Rodriguez-Torres, M.1    Stoehr, A.2    Gane, E.J.3    Serfaty, L.4    Lawitz, E.5    Zhou, A.6    Bourque, M.7    Bhanja, S.8    Strizki, J.9    Barnard, R.J.O.10
  • 25
    • 84884550531 scopus 로고    scopus 로고
    • Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
    • E. Lawitz, M. Sulkowski, I. Jacobson, W.K. Kraft, B. Maliakkal, M. Al-Ibrahim, S.C. Gordon, P. Kwo, J.K. Rockstroh, and P. Panorchan et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics Antivir Res 99 2013 214 220
    • (2013) Antivir Res , vol.99 , pp. 214-220
    • Lawitz, E.1    Sulkowski, M.2    Jacobson, I.3    Kraft, W.K.4    Maliakkal, B.5    Al-Ibrahim, M.6    Gordon, S.C.7    Kwo, P.8    Rockstroh, J.K.9    Panorchan, P.10
  • 26
    • 84884411153 scopus 로고    scopus 로고
    • Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with HCV genotype 1 infection
    • 790.e3-800.e3
    • P. Marcellin, C. Cooper, L. Balart, D. Larrey, T. Box, E. Yoshida, E. Lawitz, P. Buggisch, P. Ferenci, and M. Weltman et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with HCV genotype 1 infection Gastroenterology 145 2013 790.e3-800.e3
    • (2013) Gastroenterology , vol.145
    • Marcellin, P.1    Cooper, C.2    Balart, L.3    Larrey, D.4    Box, T.5    Yoshida, E.6    Lawitz, E.7    Buggisch, P.8    Ferenci, P.9    Weltman, M.10
  • 35
    • 84904708963 scopus 로고    scopus 로고
    • The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis
    • 10.1053/j.gastro.2014.04.006
    • M.P. Manns, J.M. Vierling, B.R. Bacon, S. Bruno, O. Shibolet, Y. Baruch, P. Marcellin, L. Caro, A.Y. Howe, and C. Fandozzi et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis Gastroenterology 2014 10.1053/j.gastro.2014.04.006
    • (2014) Gastroenterology
    • Manns, M.P.1    Vierling, J.M.2    Bacon, B.R.3    Bruno, S.4    Shibolet, O.5    Baruch, Y.6    Marcellin, P.7    Caro, L.8    Howe, A.Y.9    Fandozzi, C.10
  • 38
    • 84892806505 scopus 로고    scopus 로고
    • Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
    • e6
    • S. Zeuzem, T. Berg, E. Gane, P. Ferenci, G.R. Foster, M.W. Fried, C. Hezode, G.M. Hirschfield, I. Jacobson, and I. Nikitin et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 146 2014 430 441 e6
    • (2014) Gastroenterology , vol.146 , pp. 430-441
    • Zeuzem, S.1    Berg, T.2    Gane, E.3    Ferenci, P.4    Foster, G.R.5    Fried, M.W.6    Hezode, C.7    Hirschfield, G.M.8    Jacobson, I.9    Nikitin, I.10
  • 41
    • 84894378216 scopus 로고    scopus 로고
    • Differential sensitivity of 5′UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors
    • 812.e4-821.e4
    • Y.-P. Li, S. Ramirez, D. Humes, S.B. Jensen, J.M. Gottwein, and J. Bukh Differential sensitivity of 5′UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors Gastroenterology 146 2014 812.e4-821.e4
    • (2014) Gastroenterology , vol.146
    • Li, Y.-P.1    Ramirez, S.2    Humes, D.3    Jensen, S.B.4    Gottwein, J.M.5    Bukh, J.6
  • 42
    • 84896292745 scopus 로고    scopus 로고
    • The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection
    • P.M. Scola, L.-Q. Sun, A.X. Wang, J. Chen, N. Sin, B.L. Venables, S.-Y. Sit, Y. Chen, A. Cocuzza, and D.M. Bilder et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection J Med Chem 57 2014 1730 1752
    • (2014) J Med Chem , vol.57 , pp. 1730-1752
    • Scola, P.M.1    Sun, L.-Q.2    Wang, A.X.3    Chen, J.4    Sin, N.5    Venables, B.L.6    Sit, S.-Y.7    Chen, Y.8    Cocuzza, A.9    Bilder, D.M.10
  • 43
    • 84874095900 scopus 로고    scopus 로고
    • Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses
    • J.M. Gottwein, S.B. Jensen, Y.P. Li, L. Ghanem, T.K. Scheel, S.B. Serre, L. Mikkelsen, and J. Bukh Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses Antimicrob Agents Chemother 57 2013 1291 1303
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 1291-1303
    • Gottwein, J.M.1    Jensen, S.B.2    Li, Y.P.3    Ghanem, L.4    Scheel, T.K.5    Serre, S.B.6    Mikkelsen, L.7    Bukh, J.8
  • 49
    • 77952602256 scopus 로고    scopus 로고
    • Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease
    • X. Tong, A. Arasappan, F. Bennett, R. Chase, B. Feld, Z. Guo, A. Hart, V. Madison, B. Malcolm, and J. Pichardo et al. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease Antimicrob Agents Chemother 54 2010 2365 2370
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 2365-2370
    • Tong, X.1    Arasappan, A.2    Bennett, F.3    Chase, R.4    Feld, B.5    Guo, Z.6    Hart, A.7    Madison, V.8    Malcolm, B.9    Pichardo, J.10
  • 51
    • 84895802673 scopus 로고    scopus 로고
    • Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
    • D.L. Wyles, and J.A. Gutierrez Importance of HCV genotype 1 subtypes for drug resistance and response to therapy J Viral Hepat 21 2014 229 240
    • (2014) J Viral Hepat , vol.21 , pp. 229-240
    • Wyles, D.L.1    Gutierrez, J.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.